Skip to main content
. Author manuscript; available in PMC: 2019 Nov 17.
Published in final edited form as: Cytokine. 2018 Nov 17;111:551–562. doi: 10.1016/j.cyto.2018.09.016

Figure 5. EB1089 significantly upregulated VDR in NKL cells.

Figure 5.

The NKL cell line was treated with the indicated doses of EB1089, or appropriate negative controls, for 24 h. Total protein loaded per sample was 40 μg with β-actin used as a loading control. Representative western blots of VDR (A) and RXR-β (B) are shown. Data from three independent experiments were quantified to determine relative expression levels and quantification is shown to the right of each representative western blot. The fold change in the graphs represents VDR or RXR-β over corresponding β-actin. Repeated measures ANOVA was used to determine significance of EB1089 treatment compared to 0 nM vehicle control (* p<0.05, ** p<0.01, *** p <0.001). For graphical representation, the vehicle control was set to 1.